{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T03:03:11Z","timestamp":1791342191618,"version":"4.3.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2015,9,24]],"date-time":"2015-09-24T00:00:00Z","timestamp":1443052800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1007\/s40259-015-0140-7","type":"journal-article","created":{"date-parts":[[2015,9,24]],"date-time":"2015-09-24T02:07:05Z","timestamp":1443060425000},"page":"301-307","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Sipuleucel-T (Provenge\u00ae)\u2014Autopsy of an Innovative Paradigm Change in Cancer Treatment: Why a Single-Product Biotech Company Failed to Capitalize on its Breakthrough Invention"],"prefix":"10.1007","volume":"29","author":[{"given":"Szymon","family":"Jaros\u0142awski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mondher","family":"Toumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,9,24]]},"reference":[{"key":"140_CR1","unstructured":"National Cancer Institute. The surveillance, epidemiology, and end results stat fact sheets: prostate cancer. http:\/\/seer.cancer.gov\/statfacts\/html\/prost.html . Accessed 3 Jul 2015."},{"key":"140_CR2","unstructured":"American Cancer Society. Prostate cancer. http:\/\/www.cancer.org\/cancer\/prostatecancer\/detailedguide\/prostate-cancer-key-statistics . Accessed 3 Jul 2015."},{"issue":"2","key":"140_CR3","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.maturitas.2011.07.018","volume":"70","author":"D Vasani","year":"2011","unstructured":"Vasani D, Josephson DY, Carmichael C, Sartor O, Pal SK. Recent advances in the therapy of castration-resistant prostate cancer: the price of progress. Maturitas. 2011;70(2):194\u20136.","journal-title":"Maturitas"},{"key":"140_CR4","unstructured":"Package insert and patient information\u2014Provenge. US Food and Drug Administration. 2010. http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/CellularGeneTherapyProducts\/ApprovedProducts\/UCM210031.pdf . Accessed 10 Sep 2015."},{"key":"140_CR5","unstructured":"Provenge. Approval History. US Food and Drug Administration. 2007. http:\/\/www.fda.gov\/BiologicsBloodVaccines\/CellularGeneTherapyProducts\/ApprovedProducts\/ucm213554.htm . Accessed 3 Jul 2015."},{"key":"140_CR6","unstructured":"European Medicines Agency. Assessment report. Provenge. 2011. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002513\/WC500151101.pdf . Accessed 3 Jul 2015."},{"key":"140_CR7","unstructured":"PharmaCell. PharmaCell to finalize purchase [news release]. 2014. http:\/\/pharmacell.nl\/pharmacell-finalize-purchase-cell-therapy-production-facility\/ . Accessed 3 Jul 2015."},{"key":"140_CR8","unstructured":"National Comprehensive Cancer Network. Prostate cancer guidelines. 2010. http:\/\/www.nccn.org\/patients\/guidelines\/prostate\/index.html#38 . Accessed 3 Jul 2015."},{"key":"140_CR9","unstructured":"Dendreon. FDA approves PROVENGE(R) for the treatment of men with advanced prostate cancer. 2010 Apr 29. http:\/\/investor.dendreon.com\/releasedetail.cfm?ReleaseID=533434 . Accessed 21 Aug 2015."},{"key":"140_CR10","unstructured":"Xconomy. Dendreon sets Provenge price at $93,000, says only 2000 people will get it in first year 2010. 2013. http:\/\/www.xconomy.com\/seattle\/2010\/04\/29\/dendreon-sets-provenge-price-at-93000-says-only-2000-people-will-get-it-in-first-year\/ . Accessed 21 Aug 2015."},{"key":"140_CR11","unstructured":"FierceBiotech. How much is too much to pay for Provenge? 2010 Apr 14. http:\/\/www.fiercebiotech.com\/story\/how-much-too-much-pay-provenge\/2010-04-14 . Accessed 21 Aug 2015."},{"issue":"3 Spec No.","key":"140_CR12","first-page":"SP108","volume":"18","author":"DG Holcombe","year":"2012","unstructured":"Holcombe DG. Is Provenge angst a symbol or symptom of the times? Am J Manag Care. 2012;18(3 Spec No.):SP108\u20139.","journal-title":"Am J Manag Care"},{"issue":"4","key":"140_CR13","doi-asserted-by":"crossref","first-page":"506","DOI":"10.4161\/hv.18334","volume":"8","author":"S Simoens","year":"2012","unstructured":"Simoens S. Pharmaco-economic aspects of Sipuleucel-T. Hum Vaccin Immunother. 2012;8(4):506\u20138.","journal-title":"Hum Vaccin Immunother"},{"issue":"4","key":"140_CR14","doi-asserted-by":"crossref","first-page":"509","DOI":"10.4161\/hv.18860","volume":"8","author":"CJ Paller","year":"2012","unstructured":"Paller CJ, Antonarakis ES. Sipuleucel-T for the treatment of metastatic prostate cancer. Hum Vaccin Immunother. 2012;8(4):509\u201319.","journal-title":"Hum Vaccin Immunother"},{"issue":"18","key":"140_CR15","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1056\/NEJMp1103057","volume":"364","author":"JD Chambers","year":"2011","unstructured":"Chambers JD, Neumann PJ. Listening to Provenge. What a costly cancer treatment says about future medicare policy. N Engl J Med. 2011;364(18):1687\u20139.","journal-title":"N Engl J Med"},{"issue":"9","key":"140_CR16","first-page":"31","volume":"19","author":"E Silverman","year":"2010","unstructured":"Silverman E. Provenge approval means sensitive coverage decisions. Manag Care. 2010;19(9):31\u20134.","journal-title":"Manag Care"},{"issue":"10","key":"140_CR17","first-page":"881","volume":"24","author":"R Baghdadi","year":"2010","unstructured":"Baghdadi R. Dendreon vs CMS: why the Provenge coverage controversy is bigger than just one product. Oncology. 2010;24(10):881\u20133.","journal-title":"Oncology"},{"issue":"4","key":"140_CR18","doi-asserted-by":"crossref","first-page":"477","DOI":"10.4161\/hv.7.4.14189","volume":"7","author":"JB Dickerson","year":"2011","unstructured":"Dickerson JB. Provenge: revolutionary technology or ethical bust? Hum Vaccin. 2011;7(4):477\u201380.","journal-title":"Hum Vaccin"},{"issue":"9","key":"140_CR19","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.4161\/hv.21921","volume":"8","author":"B Jonsson","year":"2012","unstructured":"Jonsson B, Wilking N. Cancer vaccines and immunotherapeutics: challenges for pricing, reimbursement and market access. Hum Vaccin Immunother. 2012;8(9):1360\u20133.","journal-title":"Hum Vaccin Immunother"},{"key":"140_CR20","unstructured":"Usdin S. Ring-fence for Provenge. Biocentury. 2010. http:\/\/www.biocentury.com\/biotech-pharma-news\/regulation\/2010-07-05\/medicare-national-coverage-process-could-restrict-payment-for-dendreons-provenge-a28 . Accessed 3 Jul 2015."},{"key":"140_CR21","unstructured":"Usdin S. Provenge politics. Biocentury. 2011. http:\/\/www.biocentury.com\/biotech-pharma-news\/coverstory\/2011-11-21\/politics-media-drove-medicare-review-of-provenge-prostate-cancer-treatment-a1 . Accessed 3 Jul 2015."},{"key":"140_CR22","unstructured":"Centers for Medicare and Medicaid Services. National Coverage Analysis (NCA) tracking sheet for autologous cellular immunotherapy treatment of metastatic prostate cancer (CAG-00422N). http:\/\/www.cms.gov\/medicare-coverage-database\/details\/nca-tracking-sheet.aspx?NCAId=247&TAId=77&IsPopup=y&bc=AAAAAAAAAgAAAA%3D%3D& . Accessed 3 Jul 2015."},{"issue":"4","key":"140_CR23","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1093\/jnci\/djr041","volume":"103","author":"M Goozner","year":"2011","unstructured":"Goozner M. Concerns about Provenge simmer as CMS ponders coverage. J Natl Cancer Inst. 2011;103(4):288\u20139.","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"140_CR24","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.6004\/jnccn.2014.0139","volume":"12","author":"CL Gong","year":"2014","unstructured":"Gong CL, Hay JW. Cost-effectiveness analysis of abiraterone and sipuleucel-T in asymptomatic metastatic castration-resistant prostate cancer. J Natl Compr Canc Netw. 2014;12(10):1417\u201325.","journal-title":"J Natl Compr Canc Netw"},{"key":"140_CR25","unstructured":"Institute for Quality and Efficiency in Health Care (IQWIG). Sipuleucel-T in prostate cancer: indication of added benefit. 2015. https:\/\/www.iqwig.de\/en\/press\/press-releases\/press-releases\/sipuleucel-t-in-prostate-cancer-indication-of-added-benefit.6618.html . Accessed 3 Jul 2015."},{"key":"140_CR26","unstructured":"National Institute for Health and Care Excellence (NICE). Sipuleucel-T for treating asymptomatic or minimally symptomatic metastatic hormone-relapsed prostate cancer. NICE technology appraisal guidance [TA332]. 2015. https:\/\/www.nice.org.uk\/guidance\/ta332 . Accessed 3 Jul 2015."},{"key":"140_CR27","unstructured":"FierceBiotech. Dendreon: Provenge to cost $93K for full course of treatment. 2010. http:\/\/www.fiercebiotech.com\/story\/dendreon-provenge-cost-93k-full-course-treatment\/2010-04-29 . Accessed 21 Aug 2015."},{"issue":"7","key":"140_CR28","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.urolonc.2011.12.022","volume":"31","author":"J Peppercorn","year":"2013","unstructured":"Peppercorn J, Armstrong A, Zaas DW, George D. Rationing in urologic oncology: lessons from sipuleucel-T for advanced prostate cancer. Urol Oncol. 2013;31(7):1079\u201384.","journal-title":"Urol Oncol"},{"key":"140_CR29","unstructured":"Schaeffer S. Dendreon\u2019s curve ball. BioCentury. 2011. http:\/\/www.biocentury.com\/biotech-pharma-news\/strategy\/2011-08-08\/why-dendreon-stumbled-on-its-launch-of-provenge-for-prostate-cancer-a1 . Accessed 10 Sep 2015."},{"key":"140_CR30","unstructured":"FiercePharma. Payers expect Provenge sales to stay flat. 2011. http:\/\/www.fiercepharma.com\/story\/payers-expect-provenge-sales-stay-flat\/2011-08-25 . Accessed 3 Jul 2015."},{"key":"140_CR31","unstructured":"FiercePharma. Lessons from Provenge: when will MDs prescribe life-extending drugs? 2011. http:\/\/www.fiercepharma.com\/sermosurveys\/lessons-provenge-when-will-mds-prescribe-life-extending-drugs-august-31-201 . Accessed 3 Jul 2015."},{"issue":"5","key":"140_CR32","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1111\/j.1464-410X.2011.10886.x","volume":"110","author":"H Payne","year":"2012","unstructured":"Payne H, Bahl A, Mason M, Troup J, De Bono J. Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities. BJU Int. 2012;110(5):658\u201367.","journal-title":"BJU Int"},{"key":"140_CR33","unstructured":"Dendreon unlikely to develop diagnostic despite potential to allay reimbursement fears. Financial Times. 2011. http:\/\/www.ft.com\/cms\/s\/2\/d9495d4c-d26f-11e0-9137-00144feab49a.html#ixzz1WWXkrPOM . Accessed 3 Jul 2015."},{"key":"140_CR34","unstructured":"Lewis B, Sartor O. The changing landscape of metastatic prostate cancer. Am J Hematol Oncol. 2015. http:\/\/www.gotoper.com\/publications\/ajho\/2015\/2015Aug\/The-Changing-Landscape-of-Metastatic-Prostate-Cancer . Accessed 2015 Sep 10."},{"key":"140_CR35","unstructured":"Sun L. 3 investing lessons from Dendreon. The Motley Fool. 2013. http:\/\/www.fool.com\/investing\/general\/2013\/12\/04\/3-investing-lessons-from-dendreon.aspx . Accessed 2015 Sep 10."},{"key":"140_CR36","unstructured":"Dendreon reports second quarter 2011 financial results. Dendreon Inc. 2011. http:\/\/investor.dendreon.com\/releasedetail.cfm?ReleaseID=596524 . Accessed 3 Jul 2015."},{"key":"140_CR37","unstructured":"Dendreon cuts staff by 25%; high-level exec departs. Wall Street Journal Health Blog. 2011. http:\/\/blogs.wsj.com\/health\/2011\/09\/08\/dendreon-cuts-staff-by-25-high-level-exec-departs\/ . Accessed 3 Jul 2015."},{"key":"140_CR38","unstructured":"Carroll J. Dendreon shares plunge as new CEO brings out the ax (again). FiercePharma. 2012. http:\/\/www.fiercebiotech.com\/story\/dendreon-shares-plunge-new-ceo-brings-out-ax-again\/2012-07-31 . Accessed 3 Jul 2015."},{"key":"140_CR39","unstructured":"Palmer E. Sale of plant to Novartis doesn\u2019t reverse Dendreon\u2019s ill fortunes. FierceManufacturing. 2013. http:\/\/www.fiercepharmamanufacturing.com\/story\/sale-plant-novartis-doesnt-reverse-dendreons-ill-fortunes\/2013-05-09 . Accessed 3 Jul 2015."},{"key":"140_CR40","unstructured":"European Medicines Agency. Provenge. Withdrawal of the marketing authorisation in the European Union. European Medicines Agency. 2015. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Public_statement\/2015\/05\/WC500186950.pdf . Accessed 3 Jul 2015."},{"issue":"4","key":"140_CR41","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.juro.2010.07.009","volume":"184","author":"MJ Droller","year":"2010","unstructured":"Droller MJ. Citizenship in our profession. J Urol. 2010;184(4):1248\u201350.","journal-title":"J Urol"},{"issue":"6","key":"140_CR42","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/nbt0610-531","volume":"28","author":"L DeFrancesco","year":"2010","unstructured":"DeFrancesco L. Landmark approval for Dendreon\u2019s cancer vaccine. Nat Biotech. 2010;28(6):531\u20132.","journal-title":"Nat Biotech"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-015-0140-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40259-015-0140-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-015-0140-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T15:28:47Z","timestamp":1559489327000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40259-015-0140-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,24]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["140"],"URL":"https:\/\/doi.org\/10.1007\/s40259-015-0140-7","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,24]]}}}